BridgeBio Pharma (BBIO) Debt to Equity (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Debt to Equity for 7 consecutive years, with -$0.26 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 48.28% to -$0.26 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.26 through Dec 2025, up 48.28% year-over-year, with the annual reading at -$0.26 for FY2025, 48.28% up from the prior year.
- Debt to Equity hit -$0.26 in Q4 2025 for BridgeBio Pharma, up from -$0.38 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$0.14 in Q3 2021 to a low of -$0.51 in Q4 2024.
- Historically, Debt to Equity has averaged -$0.35 across 5 years, with a median of -$0.36 in 2023.
- Biggest five-year swings in Debt to Equity: plummeted 217.81% in 2021 and later skyrocketed 48.28% in 2025.
- Year by year, Debt to Equity stood at -$0.5 in 2021, then surged by 30.23% to -$0.35 in 2022, then increased by 4.1% to -$0.33 in 2023, then plummeted by 52.47% to -$0.51 in 2024, then surged by 48.28% to -$0.26 in 2025.
- Business Quant data shows Debt to Equity for BBIO at -$0.26 in Q4 2025, -$0.38 in Q3 2025, and -$0.51 in Q4 2024.